| Literature DB >> 27582365 |
B Maisch1.
Abstract
The individual amount of alcohol consumed acutely or chronically decides on harm or benefit to a person's health. Available data suggest that one to two drinks in men and one drink in women will benefit the cardiovascular system over time, one drink being 17.6 ml 100 % alcohol. Moderate drinking can reduce the incidence and mortality of coronary artery disease, heart failure, diabetes, ischemic and hemorrhagic stroke. More than this amount can lead to alcoholic cardiomyopathy, which is defined as alcohol toxicity to the heart muscle itself by ethanol and its metabolites. Historical examples of interest are the Munich beer heart and the Tübingen wine heart. Associated with chronic alcohol abuse but having different etiologies are beriberi heart disease (vitamin B1 deficiency) and cardiac cirrhosis as hyperdynamic cardiomyopathies, arsenic poising in the Manchester beer epidemic, and cobalt intoxication in Quebec beer drinker's disease. Chronic heavy alcohol abuse will also increase blood pressure and cause a downregulation of the immune system that could lead to increased susceptibility to infections, which in turn could add to the development of heart failure. Myocardial tissue analysis resembles idiopathic cardiomyopathy or chronic myocarditis. In the diagnostic work-up of alcoholic cardiomyopathy, the confirmation of alcohol abuse by carbohydrate deficient transferrin (CDT) and increased liver enzymes, and the involvement of the heart by markers of heart failure (e.g., NT-proBNP) and of necrosis (e.g., troponins or CKMb) is mandatory. Treatment of alcoholic cardiomyopathy consists of alcohol abstinence and heart failure medication.Entities:
Keywords: Atrial fibrillation; Beriberi; Cirrhotic cardiomyopathy; Hypertension; Myocarditis
Mesh:
Substances:
Year: 2016 PMID: 27582365 PMCID: PMC5013142 DOI: 10.1007/s00059-016-4469-6
Source DB: PubMed Journal: Herz ISSN: 0340-9937 Impact factor: 1.443
Fig. 1a Left ventricle from a 49-year-old man with chronic alcohol abuse. Myofibers show partly hypertrophy and atrophy. Fibrosis is present as reparative interstitial and perivascular fibrosis. HE ×320. b Electron microscopy of an endomyocardial septal biopsy from a patient with alcoholic cardiomyopathy demonstrating myofibrillar reduction and variable mitochondriae in size but increased in number. ×2190. (With kind permission from H. Frenzel and B. Schwartzkopff [22])
Fig. 2a Otto von Bollinger. (© de.wikipedia.org). b Munich beer heart. (© Philipp Mansmann in http://www.bayerische-staatszeitung.de/staatszeitung/kultur/detailansicht-kultur/artikel/bierherz.html)
Fig. 3a Left ventricle (LV) biopsy of a 53-year-old individual with an alcohol consumption of >5 drinks/day for 32 years. Perivascular increase of leukocytes and fibrosis, myocytes in variable sizes with some myocytolysis. HE ×160. b LV biopsy of the 53-year-old alcoholic with increased ICAM (intercellular adhesion molecule) expression in capillaries and small vessels. ×320. c Circulating antimyosin antibodies in the 53-year-old patient with alcoholic abuse. Indirect immunofluorescent test. Titer 1:160 ×640
Clinical work-up in alcoholic cardiomyopathy
| Work-up of | Criteria/findings |
|---|---|
| Cardiac symptoms | Fatigue, dyspnea, edema, nocturia, tachycardia |
| Noncardiac physical examination | Mental state (delirium tremens, depression, anxiety, psychosis) |
| ECG | Atrial fibrillation, complete or incomplete left or right bundle branch blocks, ST-segment and T‑wave alterations |
| Echocardiography | LV dilatation or hypertrophy, atrial dilatation, reduced shortening and ejection fraction, small pericardial effusion, mitral and tricuspid regurgitation, atrial thrombi in atrial fibrillation |
| Endomyocardial biopsy | Similar to dilated cardiomyopathy with myocyte hypertrophy or loss, reparative fibrosis, low grade leukocyte infiltration, variable, sometimes increase in Major Histocompatibility Complex(MHC) class I and II expression, immunoglobulin binding to sarcolemma and myosin; helpful in differential diagnosis of other forms of cardiomyopathies, theoretically suited for follow-up or improvement but not in common use for this purpose |
| Cardiac MRI | Helpful in ruling out other cardiomyopathies, e. g. hypertrophic cardiomyopathy, myocarditis, constrictive pericarditis |
| Cardiac CT | Only as noninvasive method to exclude coronary disease |
Markers of alcoholism and cardiac involvement
| Laboratory marker | Indicative for | Time to normalize | Monitor abstinence |
|---|---|---|---|
| Alcohol concentration | In acute alcohol intoxication | Hours | Yes |
| Mean corpuscular volume of red blood cells (MCV) | Increased | 3 months | No |
| GGT, GOT, GPT, GOT/GPT ratio | Liver disease in patients with alcohol abuse | 4 weeks | No |
| CDT (carbohydrate-deficient transferrin) | Chronic alcohol abuse | 4 weeks | No |
| Ethyl glucuronide and ethyl sulphate | High-risk drinkers | 2 days | Yes |
| Phosphatidyl ethanol | High-risk drinkers | 4 weeks | No |
| NT-proBNP | Heart failure, helpful in follow-ups | Several weeks | No |
| Troponins, CKMB | Acute myocyte destruction | 1–3 days | No |
MCV mean corpuscular volume, GGT gamma-glutamytransferase, GOT glutamic oxalacetic transaminase, GPT glutamic pyruvic transaminase, CDT carbohydrate-deficient transferrin, NT-proBNP n-terminal pro brain natriuretic peptide, CKMB creatinin kinase, muscle, brain subunit
Treatment of alcoholism and alcoholic cardiomyopathy
| Medication | Treatment goal | Dosage | Adverse reaction | Evidence |
|---|---|---|---|---|
|
| ||||
| Naltrexone | Abstinence | 50–100 mg/day (oral) | Nausea, headache, dizziness, joint and muscle pain | High |
| Acamprosate | Abstinence | 666 mg three times daily | Diarhea, pruritus, rash, altered libido | High |
| Disulfiram | Abstinence | 200 mg/day (oral) | Dizziness, rash, headache, polyneuritis, impotence, hepatotoxicity | Mixed, needs supervision |
| Nalmefene | Reduced drinking or abstinence | 18 mg/day (oral) | Dizziness, rash, headache, nausea, vomiting | Moderate |
| Diazepam | Avoid delirium | As needed | Dizziness, sleepiness | Only symptomatic |
|
| ||||
| ACE inhibitors | HF+ prognosis | As tolerated |
| High in HF |
| Betablockers | HF+ prognosis | As tolerated |
| High in HF |
| Diuretics | HF+ prognosis | As needed |
| High in HF |
| Digitalis | Rate control | According to digoxin or digitoxin level | Avoid overdosage | Moderate in atrial fibrillation (AF) |
| Anticoagulants | Avoid stroke | INR 1.8–2.2 in AF | Bleeding | High in AF |